Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 7/20 | 0.55 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.43 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | GLRA3 | O75311 | 1/20 | 0.33 |
| ▸ | GLRB | P48167 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722557 | 0.89 | LTA4H (0.64) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28320605 | 0.86 | LTA4H (0.62) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28362996 | 0.86 | LTA4H (0.62) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28257875 | 0.86 | LTA4H (0.62) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL6850602 | 0.82 | LTA4H (0.50) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL17704300 | 0.80 | LTA4H (0.56) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL2025419 | 0.78 | LTA4H (0.55) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL5571760 | 0.78 | LTA4H (0.70) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL3040421 | 0.78 | LTA4H (0.55) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 | |
| SCHEMBL3031252 | 0.78 | LTA4H (0.55) | LTA4HHPGDSCHRNA7CHRNA10CHRNA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487527-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150119370-A1 | Organic Compounds | LI PENG (US) | 2015-04-30 | — | — | US | disclosed |
| CN-104203936-A | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS INC | 2014-12-10 | — | — | CN | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2367430-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
| EP-2367430-A1 | ORGANIC COMPOUNDS | Intra-Cellular Therapies, Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7820818-B2 | Heteroaryl nitrile derivatives | NOVARTIS AG (CH) | 2010-10-26 | — | — | US | disclosed |
| WO-2010065152-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-7544688-B2 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2009-06-09 | — | — | US | disclosed |
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | NOVARTIS AG (CH) | 2006-06-29 | — | — | US | disclosed |
| EP-1537111-A1 | HETEREOARYL NITRILE DERIVATIVES | Novartis AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004020441-A1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227596-A1 | HETEROARYL NITRILE DERIVATIVES | CTSK, CTSS, CTSZ | LTA4H 782/4885HPGDS 692/4885CHRNA7 3733/4885 |
| US-20110281832-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | LTA4H 613/4885HPGDS 535/4885CHRNA7 4431/4885 |
| US-20060142575-A1 | Hetereoaryl nitrile derivatives | CTSK, CTSZ, CTSE | LTA4H 591/4885HPGDS 196/4885CHRNA7 2922/4885 |
| US-20150119370-A1 | Organic Compounds | CYP2C19, CYP2C9, CYP3A43 | LTA4H 756/4885HPGDS 1333/4885CHRNA7 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.